London, England -- (SBWIRE) -- 04/06/2012 -- GlobalData estimates that the global pancreatitis therapeutics market was worth $36m in 2011 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 3.6% to $47.7m by 2019. The current treatment options for pancreatitis offer only symptomatic relief and are primarily generic. There are no currently approved disease-modifying drugs in the market and only one in the pipeline (somatostatin). As a result, the market is expected to show slow growth until 2019.

GlobalData has found that the pancreatitis therapeutics market has significant unmet need, implying that the market is moderately served by the current products in terms of efficacy and that there is a good potential for new entrants. Pancreatitis therapies are largely targeted at reducing inflammation, pain and depression, but the current treatment options are limited. They include symptomatic treatment with simple opioid analgesics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), antidepressants and pancreatic enzyme supplements. Non selective NSAIDs and opioids are effective in the early to mid stages of pancreatitis, but often fail to provide adequate chronic pain relief. NSAIDs also cause gastrointestinal complications in a high number of patients.

The current market lacks disease-modifying drugs, resulting in significant unmet need in the treatment of pancreatitis. The only disease-modifying drug in the late stage of the pipeline is somatostatin, which is currently undergoing a university-sponsored trial. This unmet need is expected to persist during the forecast period as patients are forced to depend on symptomatic relief.

The pancreatitis therapeutics market is underserved by the currently marketed drugs. Pancrelipase is the only approved drug for chronic pancreatitis, and although it has shown high levels of safety, the same cannot be said for efficacy. As a result, there is huge potential for new entrants with drugs that can halt or reverse disease progression as well as offering good efficacy and safety profiles in both acute and chronic pancreatitis. There is also huge potential for novel therapies with better symptomatic relief.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx?ID=Pancreatitis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&companyID=sbwire

GlobalData’s analysis of the drug development pipeline shows that the late stage pipeline does not offer any immediate hope for pancreatitis patients. It consists of eight First-in-Class (FIC) molecules, but has only one disease-modifying drug, somatostatin, in the late stage of development. The FIC molecules offer distinct advantages over currently used products in terms of disease management. Research for most of them is being carried out by academic institutions and universities. Disease-modifying drugs such as ND- 07, Gala and small molecular glycan inhibitors (G family inhibitors) are in the early stage of clinical development and are not expected to impact the market during the forecast period.

GlobalData, the industry analysis specialist, has released its new report, “Pancreatitis Therapeutics – Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global pancreatitis market. It identifies the key trends shaping and driving the global market and provides insights into the prevalent competitive landscape and the emerging players expected to alter the positioning of the current leaders. Most importantly, the report provides valuable insights into the pipeline products within the global pancreatitis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Pancreatitis-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782